Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 25;295(41):13958–13964. doi: 10.1074/jbc.AC120.013788

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Felgenhauer et al.

Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — Sensitivity of SARS–CoV-2 and SARS–CoV-1 to type I IFN dose escalation. Calu-3 (A) and Vero E6 cells (B) were pretreated with recombinant human IFN-α and infected at an MOI of 0.01. Titers were measured at 24 h postinfection by plaque assay. Individual titers (dots) and geometric mean values (bars) from three biological replicates are shown. Log-transformed titers of each virus dose-response experiment were analyzed by Spearman's exact rank correlation test. CC and exact one-sided p values are provided. Note that titer values that were below the plaque assay detection level (50 PFU/ml; indicated by the dashed line) were set to 1 PFU/ml.